Phase 2 Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT07238985 Sponsor: Tanta University Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Phase 2 Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT07238985
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults over 18 years old (male or female) who have been diagnosed with fatty liver disease, confirmed through an ultrasound scan of the upper abdomen

Who may not be able to join:

  • Women who are pregnant or breastfeeding
  • People who drink more than 30 grams of alcohol per day on average (for men) or more than 20 grams per day on average (for women) (confirm with trial site for what this means in standard drinks)
  • People whose liver disease is caused by something other than fatty liver, such as viral hepatitis, a reaction to medication, or an autoimmune condition affecting the liver
  • People living with chronic kidney disease, a condition affecting the parathyroid glands (either overactive or underactive), or heart failure

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Tanta University
Registry
ClinicalTrials.gov
Start date
1 November 2025
Est. completion
20 November 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

The change in the degree of steatosis in the ultra sound and the change in fibrosis risk scores are the primary endpoint.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov